Evidence map›Paper›PMID 38396953›Full record

ArticleInternational journal of molecular sciences2024

Harvesting the Power of Green Synthesis: Gold Nanoparticles Tailored for Prostate Cancer Therapy.

Marco Oliveira, André Sousa, Sara Sá, Sílvia Soares, Ana Cláudia Pereira, Ana Catarina Rocha, Patrick Pais, Diogo Ferreira, Cátia Almeida, Carla Luís and 9 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Special Issue on Nanoparticles in Nanobiotechnology and Nanomedicine.International journal of molecular sciences · 2024
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Marco OliveiraFP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal.ORCID 0000-0002-3308-9094
André SousaFP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal.ORCID 0000-0003-1460-5361
Sara SáFP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal.ORCID 0000-0002-1376-2624
Sílvia SoaresFP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal.ORCID 0000-0002-4344-7860
Ana Cláudia PereiraFP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal.ORCID 0000-0003-1727-8255
Ana Catarina RochaFP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal.ORCID 0000-0003-4127-1694
Patrick PaisFP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal.ORCID 0000-0002-6567-6082
Diogo FerreiraFP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal.ORCID 0000-0002-2765-0586
Cátia AlmeidaFP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal.
Carla LuísFP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal.ORCID 0000-0002-5292-6337
Cláudio LimaFP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal.
Fábio AlmeidaFP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal.
Álvaro GestosoFP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal.
Miguel-Correa DuarteFFCC-Facultad de Ciencias, University of Vigo, 36310 Vigo, Spain.ORCID 0000-0003-1950-1414
Pedro BarataFP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal.
Daniela Martins-MendesFP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal.ORCID 0000-0001-9709-9948
Pilar BaylinaFP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal.ORCID 0000-0002-3740-862X
Carla F PereiraFP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal.
Rúben FernandesFP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal.ORCID 0000-0001-8933-3984

Funding

Fundação para a Ciência e Tecnologia 2022.09032.PTDCFundação para a Ciência e Tecnologia NORTE-01-0145-FEDER-024325.
6 · The paper itself

Abstract

Biosynthetic gold nanoparticles (bAuNPs) present a promising avenue for enhancing bio-compatibility and offering an economically and environmentally responsible alternative to traditional production methods, achieved through a reduction in the use of hazardous chemicals. While the potential of bAuNPs as anticancer agents has been explored, there is a limited body of research focusing on the crucial physicochemical conditions influencing bAuNP production. In this study, we aim to identify the optimal growth phase of

Indexed as

Antineoplastic AgentsMetal NanoparticlesProstatic NeoplasmsAnti-Bacterial AgentsGoldGreen Chemistry TechnologyHumansMalePlant ExtractsSpectroscopy, Fourier Transform InfraredAnti-Bacterial AgentsAntineoplastic AgentsGoldPlant Extractsanticancer activitybiosynthetic gold nanoparticlesP. aeruginosaprostate cancer

Identifiers

PMID38396953
PMCPMC10889744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.